Aptevo Therapeutics Inc. shares fell sharply in early trading, sliding 17.3% in pre-market activity to $2.15, even as the company disclosed what it described as encouraging clinical data. The Phase 1b/2 readout for the mipletamig triplet regimen showed a 93% clinical benefit rate among evaluable frontline acute myeloid leukemia (AML) patients carrying TP53 mutations - a subgroup known for poor treatment response.
Within that cohort, 14 patients were considered evaluable and 11 of those reached either complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), a 79% remission rate. That outcome was reported as substantially higher than a published historical benchmark of 41% for this patient population.
Despite the evidently positive clinical figures, the immediate market reaction was markedly negative. Traders and investors pushed the stock down ahead of the opening bell, a move the market often labels as a 'sell the news' response - particularly common among small, actively traded biotech stocks where expectations can be baked into the share price prior to an official announcement.
Investor concern is compounded by a notable dilution overhang tied to the company’s recent financing actions. Aptevo’s August 2026 warrant inducement and accompanying private investment in public equity (PIPE) arrangement created the potential for more than 6.4 million new shares to reach the market under a resale registration statement. That potential issuance is large relative to the company’s existing equity base and dwarfs the roughly 1.8 million shares of common stock reported as outstanding as of late August, creating meaningful pressure on existing holders.
The broader equity market offered only tepid support on the session. The S&P 500 was up 0.3%, the Dow Jones Industrial Average gained 0.6% and the Nasdaq Composite added 0.1% - modest gains that were insufficient to counteract APVO-specific selling pressure.
Technical indicators have also worked against the stock. Aptevo has given up the vast majority of its value from a 52-week high of $48.78 and is trading just above its 52-week low of $2.30. That extended decline has left momentum indicators persistently bearish, reinforcing downside vulnerability even in the face of favorable clinical data.
In sum, today’s pre-market sell-off reflects a convergence of factors: a positive but potentially anticipated clinical readout that did not attract new buyers, a heavy dilution overhang from recent financing activity, and a longstanding negative technical trend. Together, these elements pushed the stock toward the lower bound of its recent trading range despite the reported mipletamig efficacy in a difficult-to-treat AML subgroup.
What to watch next
- Whether the resale registration statement leads to actual share resales and the timing of any such transactions.
- Any additional clinical or regulatory updates that could alter investor perception of the mipletamig program.
- Short- and longer-term technical price action around the company’s recent lows.